

Form 51-102F3
Material Change Report

1. Name and Address of Company

Enttheon Biomedical Corp.
Suite 720 - 999 W Broadway Street
Vancouver, BC
V5Z 1K5
(the "Company")

2. Dates of Material Change(s)

March 1, 2024

3. News Release(s)

News release was issued on February 27, 2024 and disseminated via Stockwatch pursuant to section 7.1 of National Instrument 51-102.

4. Summaries of Material Changes

The Company announces that the Company confirms the effective date for the consolidation of one (1) post-consolidation share for every ten (10) pre-consolidation shares.

5. Full Description of Material Changes

News Release dated February 27, 2024— See Schedule "A".

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been omitted.

8. Executive Officer

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

9. Date of Report

This report is dated March 1, 2024

SCHEDULE "A"
to the Material Change Report dated March 1, 2024

Entheon Biomedical Announces Effective Date of Share Consolidation

VANCOUVER, BC, February 27, 2024 – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**") announces that, further to its news release dated February 21, 2024, the Company confirms the effective date for the consolidation of one (1) post-consolidation share for every ten (10) pre-consolidation shares.

Effective at the opening on Friday, March 1, 2024, the shares of the Company will commence trading on the Canadian Securities Exchange on a consolidated basis. The name and stock symbol share remain the same.

Post-Consolidation Capitalization: Unlimited common shares with no par value of which approximately 5,908,926 common shares are issued and outstanding.

Transfer Agent: Olympia Trust Company

Trading Symbol: ENBI

CUSIP Number: 29383X202 (new)

Record Date: March 4, 2024

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

<https://entheonbiomedical.com>